Canaccord Genuity Upgrades STAAR Surgical (STAA) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall Street dips on hot inflation data ahead of Nvidia earnings
- Oil rises as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Citi sees an opportunity in Oracle after ’one of the most extreme’ stock drawdowns
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
STAAR Surgical (STAA) PT Raised to $21 at Benchmark
March 17, 2014 12:45 PM EDTBenchmark maintained a Speculative Buy rating on STAAR Surgical (NASDAQ: STAA) and raised its price target to $21.00 (from $15.00). Comments follow a favorable FDA panel vote on Toric ICL.
"There were concerns over insufficient trial data, but in the end there were five "yes"... More
STAAR Surgical (STAA) Receives Favorabl FDA Panel Vote for Visian staaTICL
March 17, 2014 6:03 AM EDTSTAAR Surgical Company (Nasdaq: STAA) reported that its Visian Toric Implantable Lens or TICL received favorable votes to three questions presented to the U.S. Food and Drug Administration's (FDA) Ophthalmic Devices Panel of the Medical Devices Advisory Committee. The Ophthalmic Devices Panel reviews and evaluates data concerning the safety and effectiveness of marketed and investigational devices for use in the eye and makes recommendations to the Commissioner of Food and Drugs.
The Panel voted favorably on all three questions posed to it by the FDA's Division of Ophthalmic, Neurological and Ear,... More
